In addition, Lei et al. successfully synthesized the c-Met/CD3 bispecific antibody BS001, which not only effectively mediated tumor cell killing by T cells by bridging CD3-positive T lymphocytes and tumor cells, but also inhibited c-Met signaling and showed significant efficacy in combination with PD-L1 antibody [207]. This evidence concerns the gene MET and neoplasm.